Real-world data analysis of the clinical and economic burden and risk factors in patients with major depressive disorder with an inadequate response to initial antidepressants

References

• Bromet E, Andrade LH, Hwang I, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9:90. Jul 26
   PubMed Web of Science ®Google Scholar
• Mrazek DA, Hornberger JC, Altar CA, et al. A review of the clinical, economic, and societal burden of treatment-resistant depression: 1996–2013. Psychiatr Serv. 2014;65(8):977–987.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or serveral treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917.
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Filteau MJ, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord. 2014;156:1–7.
   PubMed Web of Science ®Google Scholar
• Ng CH, Kato T, Han C, et al. Definition of treatment-resistant depression – Asia Pacific perspectives. J Affect Disord. 2019;245:626–636.
   PubMed Web of Science ®Google Scholar
• Dold M, Bartova L, Kautzky A, et al. Psychotic features in patients with major depressive disorder: a report from the European group for the study of resistant depression. J Clin Psychiatry. 2019;80(1):e1–e7.
   PubMed Web of Science ®Google Scholar
• Cepeda MS, Reps J, Ryan P. Finding factors that predict treatment-resistant depression: results of a cohort study. Depress Anxiety. 2018;35(7):668–673.
   PubMed Web of Science ®Google Scholar
• Han K-M, Park S-C, Won E-S, et al. Evidence-based Korean pharmacological treatment guideline for depression, revised edition (III): dose increment, switching, combination, and augmentation strategy in antidepressnt therapy. J Korean Neuropsychiatr Assoc. 2013;52(5):386–401.
   Google Scholar
• Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry. 2015;76(4):e487–98.
   PubMed Web of Science ®Google Scholar
• Carter B, Strawbridge R, Husain MI, et al. Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis. Int Rev Psychiatry. 2020;32(5–6):477–490.
   PubMed Web of Science ®Google Scholar
• Bschor T, Kern H, Henssler J, et al. Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. J Clin Psychiatry. 2018;79(1):11–18.
   Web of Science ®Google Scholar
• Rogoz Z. Combined treatment with atypical antipsychotics and antidepressants in treatment-resistant depression: preclinical and clinical efficacy. Pharmacol Rep. 2013;65(6):1535–1544.
   PubMed Web of Science ®Google Scholar
• Wang HR, Bahk WM, Seo JS, et al. Korean medication algorithm for depressive disorder: comparisons with other treatment guidelines. Clin Psychopharmacol Neurosci. 2017;15(3):199–209.
   PubMed Web of Science ®Google Scholar
• Kim JA, Yoon S, Kim LY, et al. Towards actualizing the value potential of Korea health insurance review and assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Korean Med Sci. 2017;32(5):718–728.
   PubMed Web of Science ®Google Scholar
• Seo JS, Bahk WM, Wang HR, et al. Korean medication algorithm for depressive disorders 2017: third revision. Clin Psychopharmacol Neurosci. 2018;16(1):67–87.
   PubMed Web of Science ®Google Scholar
• Kim N, Cho SJ, Kim H, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in South Korea. PLoS One. 2019;14(8):e0221552.
   PubMed Web of Science ®Google Scholar
• Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. Int J Psychiatry Clin Pract. 2017;21(1):13–23.
   PubMed Web of Science ®Google Scholar
• Cepeda MS, Reps J, Fife D, et al. Finding treatment-resistant depression in real-world data: how a data-driven approach compares with expert-based heuristics. Depress Anxiety. 2018;35(3):220–228.
   PubMed Web of Science ®Google Scholar
• Gibson TB, Jing Y, Smith Carls G, et al. Cost burden of treatment resistance in patients with depression. Am J Manag Care. 2010;16(5):370–377.
   PubMed Web of Science ®Google Scholar
• Lepine BA, Moreno RA, Campos RN, et al. Treatment-resistant depression increases health costs and resource utilization. Braz J Psychiatry. 2012;34(4):379–388.
   PubMed Web of Science ®Google Scholar
• Hassan AK, Farmer KC, Brahm NC, et al. Evaluating antidepressant treatment prior to adding second-line therapies among patients with treatment-resistant depression. Int J Clin Pharm. 2016;38(2):429–437.
   PubMed Web of Science ®Google Scholar
• Balestri M, Calati R, Souery D, et al. Socio-demographic and clinical predictors of treatment resistant depression: A prospective European multicenter study. J Affect Disord. 2016;189:224–232.
   PubMed Web of Science ®Google Scholar
• Tsukazawa SK, Fife D, Shimamoto K, et al. Treatment resistant depression development from major depressive disorder: a claims database analysis in Japan. Value in Health. 2016;19(7):A843.
   Web of Science ®Google Scholar
• Fife D, Feng Y, Wang MY, et al. Epidemiology of pharmaceutically treated depression and treatment resistant depression in Taiwan. Psychiatry Res. 2017;252:277–283.
   PubMed Web of Science ®Google Scholar
• Zhou X, Keitner GI, Qin B, et al. Atypical antipsychotic augmentation for treatment-resistant depression: a systematic review and network meta-analysis. IJNPPY. 2015;18(11):pyv060.
   Web of Science ®Google Scholar
• Wang HR, Woo YS, Ahn HS, et al. Can atypical antipsychotic augmentation reduce subsequent treatment failure more effectively among depressed patients with a higher degree of treatment resistance? a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol. 2015;18(8):pyv023.
   Web of Science ®Google Scholar
• Davies P, Ijaz S, Williams CJ, et al. Pharmacological interventions for treatment-resistant depression in adults. Cochrane Database Syst Rev. 2019;12(12):CD010557.
   PubMed Web of Science ®Google Scholar
• Corey-Lisle PK, Birnbaum HG, Greenberg PE, et al. Identification of a claims data "signature" and economic consequences for treatment-resistant depression. J Clin Psychiatry. 2002;63(8):717–726.
   PubMed Web of Science ®Google Scholar
• Crown WH, Finkelstein S, Berndt ER, et al. The impact of treatment-resistant depression on health care utilization and costs. J Clin Psychiatry. 2002;63(11):963–971.
   PubMed Web of Science ®Google Scholar
• Amos TB, Tandon N, Lefebvre P, et al. Direct and indirect cost burden and change of employment status in treatment-resistant depression: a matched-cohort study using a US commercial claims database. J Clin Psychiatry. 2018;79(2):17m11725.
   PubMed Web of Science ®Google Scholar
• Mahlich J, Tsukazawa S, Wiegand F. Estimating prevalence and healthcare utilization for treatment-resistant depression in Japan: a retrospective claims database study. Drugs Real World Outcomes. 2018;5(1):35–43.
   PubMedGoogle Scholar
• Kimm H, Yun JE, Lee SH, et al. Validity of the diagnosis of acute myocardial infarction in korean national medical health insurance claims data: the Korean heart study (1). Korean Circ J. 2012;42(1):10–15.
   PubMed Web of Science ®Google Scholar